一品紅(300723.SZ):在美國風濕病學會(ACR)2023年會上展示創新藥AR882在痛風石患者中臨牀試驗研究數據
格隆匯11月17日丨一品紅(300723.SZ)公佈,公司參股公司Arthrosi參加了2023年11月11日-16日在加州聖地亞哥市舉行的美國風濕病學會(ACR)2023年會,並受邀於北京時間2023年11月16日在大會上做了最新臨牀結果的專題報吿《AR882,一種對慢性痛風和痛風石患者有效的尿酸排泄促進劑:使用DECT的全球前瞻性概念驗證試驗結果》,展示了創新藥AR882在Ⅱ期痛風石患者試驗中的積極數據。
AR882能否最終獲批,且獲批後能否最終實現商業目的均存在一定的不確定性,敬請廣大投資者注意潛在的投資風險,公司將按有關規定及時對後續進展情況履行信息披露義務。
AR882治療痛風石適應症全球Ⅱ期臨牀試驗進展對公司近期業績不會產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.